Loss of 13q14-q21 and gain of 5p14-pter in the progression of leiomyosarcoma

Modern Pathology

Volumn 16, Issue 8, 2003, Pages 778-785

  Wang, Rubin ^a   Titley, Jenny C ^a   Lu, Yong Jie ^a,c   Summersgill, Brenda M ^a   Bridge, Julia A ^b   Fisher, Cyril ^c   Shipley, Janet ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chromosome; Comparative genomic hybridization; Flow cytometry; Leiomyosarcoma; Progression

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME 5P; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DIPLOIDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MALE; MOLECULAR GENETICS; OUTCOMES RESEARCH; PLOIDY; PRIORITY JOURNAL; SURVIVAL TIME; TETRAPLOIDY; TRIPLOIDY;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE DOSAGE; HUMANS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PLOIDIES; SOFT TISSUE NEOPLASMS;

EID: 0041387331     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000083648.45923.2B     Document Type: Article

References (41)

1. Herman K, Gruchala A, Niezabitowski A, Glinski B, Lackowska B. Prognostic factors in retroperitoneal sarcomas: ploidy of DNA as a predictor of clinical outcome. J Surg Oncol 1999;71:32-5.
2. Hattinger CM, Rumpler S, Strehl S, Ambros IM, Zoubek A, Potschger U, et al. Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 1999;24:243-54.
3. Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 2000;89:793-9.
4. Rydholm A, Mandahl N, Heim S, Kreicbergs A, Willen H, Mitelman F. Malignant fibrous histiocytomas with a 19p+ marker chromosome have increased relapse rate. Genes Chromosomes Cancer 1990;2:296-9.
5. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338:153-60.
6. Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002;8:171-9.
7. Ko JL, Cheng YW, Chang SL, Su JM, Chen CY, Lee H. MDM2 mBNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer 2000;89:265-70.
8. Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CD, et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 1994;69:1052-8.
9. Yoo J, Robinson RA, Lee JY. H-ras and K-ras gene mutations in primary human soft tissue sarcoma: concomitant mutations of the ras genes. Mod Pathol 1999;12:775-80.
10. Pellin A, Boix-Ferrero J, Carpio D, Lopez-Terrada D, Carda C, Navarro S, et al. Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. Diagn Mol Pathol 1997;6:333-41.
11. Suzuki M, Ohwada M, Saga Y, Saito S, Sato I. Are DNA mismatch repair deficiencies responsible for accumulation of genetic alterations in epithelial ovarian cancers? Cancer Genet Cytogenet 2001;124:152-8.
12. Fujiwara T, Stolker JM, Watanabe T, Rashid A, Longo P, Eshleman JR, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 1998;153: 1063-78.
13. Finlay GJ. Genetics, molecular biology and colorectal cancer. Mutat Res 1993;290:3-12.
14. Riva P, Dalpr L, Gualandri V, Volont M, Miozzo M, Malgara R, et al. 19p deletion in recurring leiomyosarcoma lesions from the same patient. Cancer Genet Cytogenet 2000;119: 102-8.
15. El-Rifai W, Sarlomo-Rikala M, Knuutila S, Miettinen M. DNA copy number changes in development and progression in leiomyosarcomas of soft tissues. Am J Pathol 1998;153:985-90.
16. Evans HL, Shipley J. Leiomyosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. Pathology & genetics: tumours of soft tissue and bone. Lyon, France: IARC Press; 2002. p. 131-4.
17. Kallioniemi OP, Kallioniemi A, Sudar D, Rutovitz D, Gray IW, Waldman F, et al. Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin Cancer Biol 1993;4:41-6.
18. Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 1996;56:3220-4.
19. Ormerod MG. Analysis of DNA-general methods. In: Ormerod MG, editor. Flow cytometry. 3rd ed. Oxford, United Kingdom: Oxford University Press; 1994. p. 83-98.
20. Tanner MM, Karhu RA, Nupponen NN, Borg A, Baldetorp B, Pejovic T, et al. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 1998;153:191-9.
21. Wang R, Lu YJ, Fisher C, Bridge JA, Shipley J. Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis. Genes Chromosomes Cancer 2001;31:54-64.
22. Mandahl N, Fletcher CD, Dal Cin P, De Wever I, Mertens F, Mitelman F, et al. Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: a report from the CHAMP Study Group. Cancer Genet Cytogenet 2000;116:66-73.
23. Zhao J, de Krijger RR, Meier D, Speel EJ, Saremaslani P, Muletta-Feurer S, et al. Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am J Pathol 2000;157: 1431-8.
24. Hashimoto Y, Oga A, Okami K, Imate Y, Yamashita Y, Sasaki K. Relationship between cytogenetic aberrations by CGH coupled with tissue microdissection and DNA ploidy by laser scanning cytometry in head and neck squamous cell carcinoma. Cytometry 2000;40:161-6.
25. Plaat BE, Muntinghe FL, Molenaar WM, Hoekstra HJ, Bosveld HE, Dam A, et al. Clinical outcome of patients with previously untreated soft tissue sarcomas in relation to tumor grade, DNA ploidy and karyotype. Int J Cancer 1997;74: 396-402.
26. Murata H, Kusuzaki K, Kuzuhara A, Takeshita H, Nakamura S, Tsuji Y, et al. DNA ploidy alterations detected during dedifferentiation of periosteal chondrosarcoma. Anticancer Res 1999;19:2285-8.
27. Takeshita H, Kusuzaki K, Kuzuhara A, Tsuji Y, Ashihara T, Gebhardt MC, et al. Relationship between histologic grade and cytofluorometric cellular DNA and RNA content in primary bone tumors. Anticancer Res 2001;21:1271-7.
28. Ferno M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D. Flow cytometric DNA index and S phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol 1992;31:157-65.
29. Baba H, Korenaga D, Kakeji Y, Haraguchi M, Okamura T, Maehara Y. DNA ploidy and its clinical implications in gastric cancer. Surgery 2002;131:S63-70.
30. Abou-Rebyeh H, Borgmann V, Nagel R, Al-Abadi H. DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer 2001;92:2280-5.
31. Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Gusterson BA, et al. Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 1989;60:202-5.
32. Huang XP, Wei F, Liu XY, Xu X, Hu H, Chen BS, et al. Allelic loss on 13q in esophageal squamous cell carcinomas from northern China. Cancer Lett 2002;185:87-94.
33. Ogawara K, Miyakawa A, Shiba M, Uzawa K, Watanabe T, Wang XL, et al. Allelic loss of chromosome 13q14.3 in human oral cancer: correlation with lymph node metastasis. Int J Cancer 1998;79:312-7.
34. Derre J, Lagace R, Nicolas A, Mairal A, Chibon F, Coindre JM, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 2001;81:211-5.
35. Hu J, Khanna V, Jones M, Surti U. Genomic alterations in uterine leiomyosarcomas: potential markers for clinical diagnosis and prognosis. Genes Chromosomes Cancer 2001; 31:117-24.
36. Ozaki T, Schaefer KL, Wai D, Buerger H, Flege S, Lindner N, et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 2002;102:355-65.
37. Mandahl N, Gustafson P, Mertens F, Akerman M, Baldetorp B, Gisselsson D, et al. Cytogenetic aberrations and their prognostic impact in chondrosarcoma. Genes Chromosomes Cancer 2002;33:188-200.
38. Saretzki G, Petersen S, Petersen I, Kolble K, von Zglinicki T. hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines. Cancer Lett 2002;176:81-91.
39. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001;1:152-6.
40. Rettenberger G, Adham IM, Engel W, Klett C, Hameister H. Assignment of the porcine acrosin gene, ACR, to chromosome 5p15 by fluorescence in situ hybridization (FISH). Mamm Genome 1995;6:60-1.
41. Wurl P, Kappler M, Meye A, Bartel F, Kohler T, Lautenschlager C, et al. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 2002;359:943-5.